Home/Pipeline/mGlu2 NAM Program for TRD

mGlu2 NAM Program for TRD

Treatment-Resistant Depression

Pre-clinicalActive

Key Facts

Indication

Treatment-Resistant Depression

Phase

Pre-clinical

Status

Active

Company

Camino Pharma

About Camino Pharma

Camino Pharma is a private, preclinical-stage biotech company pioneering novel allosteric modulators for oncology and neuropsychiatric disorders. Its core expertise lies in targeting historically difficult protein classes like PTPs and GPCRs, with programs in cancer signaling, addiction, and treatment-resistant depression. The company is led by a seasoned founder-CEO with a track record of venture fundraising and drug development, and it maintains strong academic ties with the Sanford Burnham Prebys Medical Discovery Institute. While still pre-revenue, it has secured non-dilutive grant funding from the National Institute on Drug Abuse (NIDA) for its addiction program.

View full company profile

Therapeutic Areas

Oncology Central Nervous System (CNS) Disorders

Other Treatment-Resistant Depression Drugs

Drug	Company	Phase	Status
DB104 (Liafensine)	Denovo Biopharma	Phase 2b	Active
VNS Therapy for TRD	LivaNova	PMA Supplement	Active - Commercial Expansion
Precision Radiomodulation Research	ZAP Surgical	Feasibility Study	Active
NOE-101 (basimglurant)	Noema Pharma	Phase 2b	Active
PCN-101 (R-ketamine)	Perception Neuroscience	Phase 2a	Active
TAK-653	Thermo Fisher Scientific	Phase 2	Recruiting
SPN-820/821	Supernus Pharmaceuticals	Phase 3	Active
BPL-003	atai Life Sciences	Phase 2	Active
VLS-01	atai Life Sciences	Phase 2	Active